Current studies on quality of Chinese patent drugs with consistency as core and discussions on new high-quality evaluation model.
10.19540/j.cnki.cjcmm.20200506.601
- Author:
An-Yi ZHAO
1
;
Feng-Yan NI
2
;
Peng-Yue CHEN
3
;
Yan LIU
4
;
An LIU
4
Author Information
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Pharmacy,Shanxi Medical University Taiyuan 030001, China.
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Jiangxi University of Traditional Chinese Medicine Nanchang 330004, China.
3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Pharmacy, Hebei University Baoding 071002, China.
4. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent drugs;
consistency;
high quality and excellent price;
quality
- MeSH:
Drugs, Chinese Herbal;
Medicine, Chinese Traditional;
Nonprescription Drugs
- From:
China Journal of Chinese Materia Medica
2020;45(15):3740-3748
- CountryChina
- Language:Chinese
-
Abstract:
The consistency of quality on Chinese patent drugs is a hotspot and difficulty in the control of traditional Chinese medicine preparations, and has become one of the bottlenecks restricting its internationalization. Based on the analysis of current studies on quality and problems of Chinese patent drugs, this paper explored relevant methods of quality evaluation on Chinese patent drugs and possible factors affecting the consistency of quality in the pharmaceutical cycle by consulting relevant literatures about quality evaluation methods and consistency control techniques of large-scale Chinese patent drugs. And it put forward the evaluation system on high-quality Chinese patent drugs with "consistency" as the core, so as to promote the overall improvement of the quality of Chinese patent drugs, guide the rational price of Chinese patent drugs of the same species, and provide a new reference model for the quality evaluation of Chinese patent drug.
